Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study. [PDF]
PLoS ONE, 2014 The effect of hemodialysis on the plasma glucose profile and liraglutide level after liraglutide injection was investigated in patients with diabetes and end-stage renal disease (ESRD).
Takeshi Osonoi +6 more
doaj +5 more sources
Liraglutide alleviates sepsis-associated encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis [PDF]
European Journal of Medical ResearchObjective To explore the relevant mechanisms and principles by which liraglutide alleviates sepsis-associated encephalopathy (SAE) through reducing neuronal injury, glial cell activation and mitochondrial dysfunction.
Xiaoming Li +6 more
doaj +2 more sources
Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus [PDF]
PeerJ, 2021 Accumulating evidence has suggested the importance of gut microbiota in the development of type 2 diabetes mellitus (T2DM). In the present study, 40 patients with T2DM were treated with liraglutide for 4 months. Feces samples and clinical characteristics
Junjie Shang +9 more
doaj +2 more sources
Liraglutide; A New Hope for Obese Diabetics [PDF]
JLUMHS, 2020 OBJECTIVE: To assess the effectiveness of liraglutide in reducing weight and Glycated haemoglobin (HbA1c) in type 2 diabetic patients. METHODOLOGY: This analytical observational study was conducted at Jinnah medical college hospital Karachi Pakistan ...
Ajeet Kumar +6 more
doaj +1 more source
Pharmaceuticals, 2022 Diabetes is commonly treated with glucagon-like peptide-1 receptor (GLP-1R) agonists including liraglutide and others. However, liraglutide was found to raise plasma glucose levels in normal rats.
Chia-Chen Hsu +4 more
doaj +1 more source
Cells, 2022 The impairment in endothelial progenitor cell (EPC) functions results in dysregulation of vascular homeostasis and dysfunction of the endothelium under diabetic conditions.
Xiaoqing Yan +16 more
doaj +1 more source
Liraglutide and Exercise: A Possible Treatment for Obesity?
Obesities, 2022 (1) Background: Obesity has become an important public health problem worldwide, and its characterization as a chronic disease reflects the impact of a complex and multifactorial condition.
Ana Paula Azevêdo Macêdo +4 more
doaj +1 more source
Journal of Analytical Science and Technology, 2023 Liraglutide is a glucagon-like peptide-1 (GLP-1) analog that has been utilized for the treatment of type 2 diabetes mellitus. Liraglutide at a higher dose also shows beneficial effects in weight loss, which prompted its widespread use as an anti-obesity ...
Hyeon Seok Oh +7 more
doaj +1 more source
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks. DUAL VIII, a randomized trial designed to resemble clinical practice [PDF]
, 2020 This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N =
Aroda, V. R. +7 more
core +1 more source
Pharmaceuticals, 2020 Liraglutide, an acylated analog of glucagon-like peptide 1 (GLP-1), could improve glycemic control in diabetes. Moreover, endogenous opioid peptides play a role in blood sugar regulation.
Kai-Chun Cheng +4 more
doaj +1 more source